These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10473224)

  • 1. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic.
    Candiani G; Abbondi M; Borgonovi M; Romanò G; Parenti F
    J Antimicrob Chemother; 1999 Aug; 44(2):179-92. PubMed ID: 10473224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.
    Goldstein BP; Candiani G; Arain TM; Romanò G; Ciciliato I; Berti M; Abbondi M; Scotti R; Mainini M; Ripamonti F
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1580-8. PubMed ID: 7492108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycopeptide tolerance in bacteria causing endocarditis.
    Perry JD; Jones AL; Gould FK
    J Antimicrob Chemother; 1999 Jul; 44(1):121-4. PubMed ID: 10459820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
    Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
    Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.
    Berti M; Candiani G; Borgonovi M; Landini P; Ripamonti F; Scotti R; Cavenaghi L; Denaro M; Goldstein BP
    Antimicrob Agents Chemother; 1992 Feb; 36(2):446-52. PubMed ID: 1534978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent.
    Jones RN; Biedenbach DJ; Johnson DM; Pfaller MA
    J Chemother; 2001 Jun; 13(3):244-54. PubMed ID: 11450881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns.
    Marchese A; Debbia EA; Bacca D; Balistreri G; Musolino B; Schito GC
    Drugs; 1997; 54 Suppl 6():11-20. PubMed ID: 9474477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium.
    Fantin B; Leclercq R; Arthur M; Duval J; Carbon C
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1570-5. PubMed ID: 1834013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
    Harland S; Tebbs SE; Elliott TS
    J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis.
    Lefort A; Arthur M; Depardieu F; Chau F; Pouzet C; Courvalin P; Fantin B
    J Infect Dis; 2004 Jan; 189(1):90-7. PubMed ID: 14702158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.
    Gorzynski EA; Amsterdam D; Beam TR; Rotstein C
    Antimicrob Agents Chemother; 1989 Nov; 33(11):2019-22. PubMed ID: 2532875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of a European collaborative study on comparative susceptibility of gram-positive clinical isolates to teicoplanin and vancomycin.
    Grüneberg RN; Hryniewicz W
    Int J Antimicrob Agents; 1998 Nov; 10(4):271-7. PubMed ID: 9916900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Campoli-Richards DM; Brogden RN; Faulds D
    Drugs; 1990 Sep; 40(3):449-86. PubMed ID: 2146108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotics for gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2000 Jun; 14(2):463-74. PubMed ID: 10829266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of VanD type resistance on activities of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecium.
    Lefort A; Garry L; Depardieu F; Courvalin P; Fantin B
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3515-8. PubMed ID: 14576110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality assessment of glycopeptide susceptibility tests: a European collaborative study. European Glycopeptide Resistance Group.
    Brown DF; Courvalin P
    Int J Antimicrob Agents; 1997 Jan; 9(3):153-63. PubMed ID: 9552711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
    Felmingham D; Brown DF; Soussy CJ
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens.
    Streit JM; Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):307-10. PubMed ID: 15922534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.